In this video, health-care analysts David Williamson and Max Macaluso discuss the cutting edge of insulin treatments, including a new long-acting insulin by Sanofi. The pharma currently dominates the insulin market, but generic competition is on the way. Watch as David and Max discuss whether Sanofi's newest insulin in development, U300, can use better performance to hold on to the company's market share.